BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 36335649)

  • 1. Annulated pyrazole derivatives as a novel class of urokinase (uPA) inhibitors: Green synthesis, anticancer activity, DNA-damage evaluation, and molecular modelling study.
    Farag PS; AboulMagd AM; Hemdan MM; Hassaballah AI
    Bioorg Chem; 2023 Jan; 130():106231. PubMed ID: 36335649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel pyrazole-based COX-2 inhibitors as potential anticancer agents: Design, synthesis, cytotoxic effect against resistant cancer cells, cell cycle arrest, apoptosis induction and dual EGFR/Topo-1 inhibition.
    Halim PA; Sharkawi SMZ; Labib MB
    Bioorg Chem; 2023 Feb; 131():106273. PubMed ID: 36444790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
    Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
    Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
    Bakr RB; Mehany ABM; Abdellatif KRA
    Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, modeling studies and biological evaluation of pyrazole derivatives linked to oxime and nitrate moieties as nitric oxide donor selective COX-2 and aromatase inhibitors with dual anti-inflammatory and anti-neoplastic activities.
    A A Fadaly W; A M M Elshaier Y; T M Nemr M; R A Abdellatif K
    Bioorg Chem; 2023 May; 134():106428. PubMed ID: 36893546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological Activity, Apoptotic Induction and Cell Cycle Arrest of New Hydrazonoyl Halides Derivatives.
    Mohamed MF; Hassaneen HM; Elzayat EM; El-Hallouty SM; El-Manawaty M; Saleh FM; Mohamed Y; El-Zohiry D; Fahmy G; Abdelaal N; Hassanin N; Hossam N
    Anticancer Agents Med Chem; 2019; 19(9):1141-1149. PubMed ID: 30843494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tetrahydroindolocarbazoles (THICZs) as new class of urokinase (uPA) inhibitors: Synthesis, anticancer evaluation, DNA-damage determination, and molecular modelling study.
    El-Sharief MAMS; El-Naggar MH; Ahmed EM; El-Messery SM; Mahmoud AE; Ali MM; Salem LM; Mahrous KF; El Sayed MT
    Bioorg Chem; 2018 Oct; 80():545-554. PubMed ID: 30014922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
    Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
    Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of novel heterocyclic compounds based on 4-aryl-4H-chromene scaffold as anticancer agents: Design, synthesis, antiprofilerative activity against resistant cancer cells, dual β-tubulin/c-Src inhibition, cell cycle arrest and apoptosis induction.
    Abdelall EKA; A H Elshemy H; Labib MB; E A Mohamed F
    Bioorg Chem; 2022 Mar; 120():105591. PubMed ID: 34998122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of pyrolo[2,3-c]pyrazole, pyrolo[2,3-d]pyrimidine and their bioisosteres as novel CDK2 inhibitors with potent in vitro apoptotic anti-proliferative activity: Synthesis, biological evaluation and molecular dynamics investigations.
    Azmy EM; Hagras M; Ewida MA; Doghish AS; Gamil Khidr E; El-Husseiny AA; Gomaa MH; Refaat HM; Ismail NSM; Nassar IF; Lashin WH
    Bioorg Chem; 2023 Oct; 139():106729. PubMed ID: 37467621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
    Maher M; Kassab AE; Zaher AF; Mahmoud Z
    Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, molecular docking and anti-proliferative evaluations of [1,2,4]triazolo[4,3-a]quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors.
    El-Adl K; El-Helby AA; Sakr H; Elwan A
    Bioorg Chem; 2020 Dec; 105():104399. PubMed ID: 33113414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of new quinoxaline-2(1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation.
    El-Adl K; Sakr HM; Yousef RG; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; Abulkhair HS; Eissa IH
    Bioorg Chem; 2021 Sep; 114():105105. PubMed ID: 34175720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
    Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
    Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A New Series of Cytotoxic Pyrazoline Derivatives as Potential Anticancer Agents that Induce Cell Cycle Arrest and Apoptosis.
    Wang H; Zheng J; Xu W; Chen C; Wei D; Ni W; Pan Y
    Molecules; 2017 Sep; 22(10):. PubMed ID: 28961210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and molecular docking of novel pyrazole-chalcone analogs of lonazolac as 5-LOX, iNOS and tubulin polymerization inhibitors with potential anticancer and anti-inflammatory activities.
    Ahmed AHH; Mohamed MFA; Allam RM; Nafady A; Mohamed SK; Gouda AE; Beshr EAM
    Bioorg Chem; 2022 Dec; 129():106171. PubMed ID: 36166898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Docking and In Vitro Anticancer Screening of Synthesized Arylthiazole linked 2H-indol-2-one Derivatives as VEGFR-2 Kinase Inhibitors.
    Shalmali N; Bawa S; Ali MR; Kalra S; Kumar R; Zeya B; Rizvi MA; Partap S; Husain A
    Anticancer Agents Med Chem; 2022; 22(11):2166-2180. PubMed ID: 34792005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, anticancer evaluation and molecular docking studies of new heterocycles linked to sulfonamide moiety as novel human topoisomerase types I and II poisons.
    Halawa AH; Elgammal WE; Hassan SM; Hassan AH; Nassar HS; Ebrahim HY; Mehany ABM; El-Agrody AM
    Bioorg Chem; 2020 May; 98():103725. PubMed ID: 32199303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanochemical Synthesis and Molecular Docking Studies of New Azines Bearing Indole as Anticancer Agents.
    Ibrahim MS; Farag B; Al-Humaidi JY; Zaki MEA; Fathalla M; Gomha SM
    Molecules; 2023 May; 28(9):. PubMed ID: 37175279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.